Myelodysplastic Syndromes Clinical Trials in Atlanta, Georgia

6 studies are recruiting for myelodysplastic syndromes in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

   This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Emory Winship Cancer Institute, Atlanta, Georgia

   Locations

   32 in total

   Run by

   Disc Medicine, Inc

   See if you can join NCT05320198 on ClinicalTrials.gov

2. A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

   This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.

   Stage

   Phase 1

   Ages

   12 to 78

   Site

   Emory University, Atlanta, Georgia

   Locations

   12 in total

   Run by

   Orca Biosystems, Inc.

   See if you can join NCT03802695 on ClinicalTrials.gov

3. Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

   The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will re…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Emory University, Atlanta, Georgia

   Locations

   30 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT02074839 on ClinicalTrials.gov

4. A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

   Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (o…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Emory - Winship Cancer Institute, Atlanta, Georgia

   Locations

   71 in total

   Run by

   Taiho Oncology, Inc.

   See if you can join NCT04256317 on ClinicalTrials.gov

5. Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

   This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Emory University, Atlanta, Georgia

   Locations

   7 in total

   Run by

   Syntrix Biosystems, Inc.

   See if you can join NCT04245397 on ClinicalTrials.gov

6. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Atlanta, Georgia

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov